Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment

Christian Confavreux [*], Sandra Vukusic

Service de Neurologie A, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677 Lyon-Bron Cedex 03, France

Abstract

There is convincing evidence that neurological relapses in multiple sclerosis (MS) are the clinical counterpart of acute focal inflammation of the central nervous system (CNS) whereas neurological progression is that of chronic diffuse neurodegeneration. The classical view is to consider that MS is an organ-specific autoimmune disease, i.e. that inflammation is the cause of the neurodegeneration. The succession of relapses eventually leads to accumulation of disability and clinical progression results from subclinical relapses. A series of recent observations tends to challenge this classical concept.

Important observations have come from the study of the natural history of MS. In the Lyon MS cohort, accumulation of irreversible disability appeared not to be affected by clinically detectable neurological relapses. This has also been shown to be "amnesic" for the early clinical characteristics of the disease, and essentially age-dependent. Suppressing relapses by disease-modifying agents does not dramatically influence the progression of irreversible disability. Interferons β reduce the relapse rate by 30% and conventional MRI activity by more than 50%. In spite of this effect on inflammation, the effect on disability is only marginal and possibly relapse-reduction-dependent. Administration of Campath-1H to patients with very active disease in terms of frequency of relapses, accumulation of disability and MRI activity, results in a profound, prolonged lymphopenia and the suppression of clinical and MRI activity, but in spite of this, clinical disability and cerebral atrophy still progress. The same experience has been reported with cladribine and autologous haematopoietic stem cell transplantation.

All these observations give support to the fact that relapses do not essentially influence irreversible disability in the long term in MS. They are consistent with what has been shown at the individual level in the 1970s by performing serial quantitative neurological examinations over several years, and with what is currently emerging from early and serial structural brain MRI studies. These breakthroughs have immediate implications for the counselling of patients with MS. They suggest that MS is as much neurodegenerative as inflammatory, and should cause the modification of disease-modifying therapeutic strategies by focussing on the protection and repair of the nervous system and not only on the control of inflammation.

1. Introduction

The course of multiple sclerosis (MS) may be looked upon as the interaction between two clinical phenomena, relapses and progression, the latter being defined as a steady worsening of symptoms and signs over a minimum of 6 months [1–3], or even 12 months according to recent definitions [4,5]. It is also an interaction between two biological phenomena in the central nervous system (CNS), i.e. inflammation, which is focal, disseminated, acute and recurrent, and degenera-

tion, which is diffuse, early, chronic and progressive. There is strong evidence that relapses are the clinical counterpart of acute focal inflammation of the CNS [6]. There is also growing evidence that progression is the clinical counterpart of chronic and progressive neurodegeneration [7,8]. One of the central issues with respect to outcome in MS is the mechanism of accrual of irreversible disability [8–10]. It may be the result of relapses with sequelae ("relapse-driven") as well as from progression ("progression-driven"). The question arises about the respective contributions of relapses and progression, and of focal inflammation and diffuse degeneration in this cumulative process. The classical view is to consider MS as an organ-specific autoimmune disease. This

_____

* Corresponding author. Tel.: +33 4 72 35 75 25; fax: +33 4 72 68 13 10.
  E-mail address: christian.confavreux@chu-lyon.fr (C. Confavreux).

means that inflammation is responsible for the initiation of the degeneration of the CNS. Does this mean that inflammation is also responsible for the perpetuation and progression of neurodegeneration? In such case, the relapses might be the major cause of the accumulation of irreversible disability in MS.

2. Relapses are a major cause of irreversible disability

At first glance this assertion is attractive. Relapses may be an important cause of disability in MS. This is a charcateristic of borderline forms of MS, such as Devic's neuromyelitis optica, transverse myelitis, acute disseminated encephalomyelitis and Marburg disease, although it is precisely because they are so devastating that they are not considered as typical MS. Relapse-driven irreversible disability may also be a feature of more classical cases of MS. Clinicians are familiar with anecdotal cases with a definitive neurological deficit brought about by a relapse. Among the 1562 patients of the Lyon's Natural History Cohort with an relapsing-remitting onset of MS (RRMS), 274 (18%) suffered from an initial relapse with irreversible incomplete recovery as defined by a score of ≥ 3 on the Kurtzke scale; among the 1288 patients with a complete recovery as defined by a DSS score ≤ 2, after the initial relapse, 391 (30%) later experienced incomplete recovery from a subsequent relapse [11]. A detailed analysis of pooled data from 224 patients with RRMS enrolled in the placebo arms of several randomized clinical trials made possible a comparison of EDSS assessments prior to, at the time of, and after a relapse of MS [12]. The baseline EDSS assessment was defined as the most recent one preceding the relapse. Comparing post-relapse and baseline evaluations, the net increase in the EDSS score was 0.27 ± 1.04 (mean $\pm$ S.D.; median = 0). This corresponds to 42% of the patients with a ≥ 0.5 and 28% with a ≥ 1.0 EDSS point increase. In this study however, the median time between evaluations performed during and after the relapse was only 63 days (range 32–140 days).

Similarly, the assessment of the possible effect of the degree of recovery from the initial neurological episode, of the time from the initial episode to the second episode and of the number of relapses during the first years of the disease, on the disability accrual process, gives the same results in natural history MS cohorts. Incomplete recovery from the initial episode, a short interval between the first two episodes and a high number of relapses during the first years of the disease are associated with a rapid accumulation of irreversible disability [11,13–15]. Brain MRI studies of cases of MS, with recent onset or of the first neurological episodes suggestive of MS, consistently show tissue destructuration with axonal loss in the acute lesions. Recent pathological studies of MS brain tissue have provided convincing explanations of the causal effect of relapses on the accu-

mulation of irreversible disability. Focal inflammation can indeed lead to focal tissue destruction with demyelination, astrocytic gliosis and, more importantly, axonal transsection [16,17].

3. Relapses are not the major cause of irreversible disability

The actual contribution of relapses to disability accumulation is not clear. Inflammation also has some beneficial effects, the best evidence being that remission is the rule following a relapse. Some experimental data have also shown that inflammation may have a neuroprotective effect [18]. Other evidence comes from the primary progressive forms of MS: progression of irreversible disability occurs without superimposed relapses [19] and without clearcut inflammation as seen pathologically and by MRI. The rate of progression of disability in these cases is similar to that of the progressive-relapsing forms of MS, i.e. the forms with a progressive onset and superimposed relapses [9,20,21].

Instructive observations have been made on pooled data from 313 patients with relapsing-remitting MS enrolled in the placebo arms of two large phase III trials of interferon β-1a [22] and glatiramer acetate [23], assessed at 3-month intervals with a 2-year follow-up [24]. Analyses were performed on the 289 patients with complete 2-year data of EDSS assessments. According to the observed course of their EDSS score throughout the 2 years of follow-up, 29% of the patients could be classified as progressors with confirmation at 3 months but, among these progressors, the EDSS increase was still present in only about half of them at the end of the follow-up period. These results clearly show that an increase in disability confirmed at 3 or even 6 months must not be considered equivalent to an irreversible increase in disability. Lublin et al. [12] also found a ≥ 1.0 1 EDSS point increase relatively to baseline in 28% of their patients at a median of 63 days after a relapse in a similar group of patients. This suggests that, in the available placebo cohorts of RRMS patients, confirmed disability increases were mainly relapse-driven; clearly, a short-term confirmed increase in disability is often relapse-driven and reversible. The issue of long-term irreversible progression of disability is quite different. Lessons from natural history MS cohorts have been informative in this respect. The statistical analysis of 1844 patients of the Lyon Natural History MS Cohort, focused on robust landmarks of disability that could easily be identified by successive neurological assessments as well as by a retrospective interview of the patient whenever necessary. They were DSS 4, defined by walking without aid for a limited distance, exceeding 500 m without rest; DSS 6, walking with unilateral support for a distance not exceeding 100 m without rest; and DSS 7, home restriction, a few steps still being possible with holding on to a wall or furniture but not exceeding 10 m without rest. Disability was defined as irreversible when a definite step had

Fig. 1. Kaplan–Meier estimates of the time from the onset of MS to the assignment of a score of 4 on the Kurtzke DSS (panel A) and the time from a score of 4 to 6 (panel B) in 1844 MS patients, according to the initial course [9] (reproduced with permission from the *New England Journal of Medicine*).


Fig. 2. Kaplan–Meier estimates of the time from a score of 4 on the Kurtzke DSS to a score of 6 in 496 patients with secondary progressive MS (Panel A) and in 282 patients with progressive onset of MS (Panel B), according to the presence or absence of superimposed relapses [9] (reproduced with permission from the *New England Journal of Medicine*).

been reached that persisted for at least 6 months, excluding any transient worsening of disability due to a relapse. This irreversibility was confirmed in all subsequent assessments during a year-long follow-up. In this cohort, we found a definite difference between patients with an RR course and those with a progressive one: the median time from the onset of MS to a score of 4 of irreversible disability on the DSS scale was significantly higher in the RR cases than in the progressive ones (Fig. 1A); the same observation was made for the time of onset of MS to assignment of a score of 6 or 7. This is in agreement with previous analyses of this cohort [13] and with the results of many other series [14,15,25–31]. Progression of irreversible disability from a score of 4 to 6 was the same in RR cases as in progressive ones (Fig. 1B; as it was for progression of disability from a score of 4 to 7, and from a score of 6 to 7 [9]. This can be interpreted as signifying that the rate of progression of irreversible disability from a score

of 4 is not affected by the presence or absence of relapses, i.e. of a RR phase preceding the chronic-progressive phase of MS.

The same material made it possible to assess the influence of the presence or absence of superimposed relapses during the progressive phase, either primary or secondary [9]. Progression of irreversible disability from a score of 4 to 6 in primary progressive cases was similar whether relapses were superimposed or not (Fig. 2A), as was the progression from a score of 4 to 6 in secondary progressive cases with or without superimposed relapses (Fig. 2B). It is obvious that a dissociation exists between relapses and progression in MS. Our results are in accordance with, and extend those from other studies on the natural history of multiple sclerosis [18,19,31].

These results from the Lyon cohort were obtained by looking only at relapses as present or absent, in a binary way. The same conclusions were reached by analysing the possible influence of relapses at the onset and during the early years of the disease with respect to their number and frequency, the degree of recovery and the time period to the second neurological episode. A shorter time interval to a second neurological episode correlated with shorter median times from onset of MS to assignment of DSS scores of 4, 6 and 7 [11]. Similar observations have been made in many other series [13,26,28,29,32–48]. The originality of the Lyon's study is that it assessed the possible influence of the same clinical variables on the progression of irreversible disability from the time of assignment of a score of 4 to 6, as well as from a score of 4 to 7 and from a score of 6 to 7 [9]. None of these variables were predictive of the time course of disability past this point (Fig. 3), which is in accordance with the results seen


Fig. 3. Kaplan–Meier estimates of the time from the onset of MS to a score of 4 (panel A) and from a score of 4 to 6 (panel B) on the Kurtzke DSS in 1844 MS patients, according to the age of the patient at the onset of the disease. (a) 0–19 years, (b) 20–29 years, (c) 30–39 years, (d) 40–49 years and (e) ≥50 years [11] (reproduced with permission from *Brain*).

in primary progressive MS [20]. Progression of irreversible disability appears to be amnesic for the clinical characteristics of the relapses which occurred during the initial stages of the disease.

Additional arguments are derived from the use of disease-modifying drugs. Treatment with β-interferons results in a 30% reduction of the relapse rate, and to a more than 50% reduction in conventional MRI activity. Despite this strong effect on inflammation, the influence of interferons on disability and brain atrophy is only marginal [22,49–52]. The use of potent immunosuppressive agents has also proven to be instructive: Campath-1H is a humanized monoclonal antibody with a powerful lymphocyte-depleting activity; its use in MS patients with a high relapse rate, rapid accumulation of disability and high MRI activity resulted in a profound and prolonged lymphopenia, and the suppression of clinical and MRI activity [53], but clinical disability and cerebral atrophy still progressed [54]. Similar conclusions can be drawn from the use of mitoxantrone and cyclophosphamide: their efficacy in very active MS with successive relapses at close intervals and accumulating disability has been demonstrated [55,56], but despite this strong and effective anti-inflammatory activity with the suppression of relapses and the reduction of the relapse-driven disability, it is not unusual to observe secondary progression of disability in these patients a few years later. In our experience and that of others, administration of these drugs in progressive MS with a standard relapse rate or no superimposed relapse at all, is not very helpful. A similar conclusion has been reached in the trial of the lymphocytotoxic drug cladribine in progressive MS patients: despite a strong and prolonged anti-inflammatory effect by MRI criteria, no beneficial effect could be observed on disability progression [57], or the development of brain atrophy [58] and T1 "black holes" [59]. In 10 patients with rapidly evolving secondary-progressive MS treated with autologous haematopoietic stem cell transplantation, followed up to 24 months, brain tissue loss still progressed despite profound and sustained suppression of concomitant visible MRI-visible inflammation [60]. Such discrepancies are not unique to MS: in rheumatoid arthritis, another chronic inflammatory disease, disease-modifying drugs have a well-established efficacy in decreasing markers of inflammation, such as erythrocyte sedimentation rate and swollen joint counts, whereas radiologically-monitored progression of irreversible joint destruction continues [61–62].

All of these observations have been collected using statistical analysis of groups of patients with MS. They are consistent with what was shown at the individual level in the 1970s. When performing serial quantitative neurological examinations over several years, it appeared that in the majority of MS patients, regression analysis revealed that progression of neurological abnormalities followed a linear or curvilinear curve (exponential, parabolic, etc.), but with only a small inflexion, even in cases with a relapsing-remitting course or with superimposed relapses during the progressive phase of the disease [38,63].

4. Is there a dissociation between relapses and progression of disability, and between focal inflammation and diffuse degeneration?

All these observations are, in fact, rather puzzling. Clinicians learn directly from patients and are apt to recall the most striking experiences; thus all neurologists will remember the patient with MS who had a relapse with a permanent deficit. There are many instances in medicine in general, and in MS in particular, of anecdotal, experience-based clinical impressions that have been clearly refuted by appropriate large-scale epidemiological studies. With respect to MS, the influence of pregnancy [64] or of vaccinations [65] on the course of the disease are good examples. However, puzzling it may be, the results of statistical analyses of population studies, indicate that relapses are not important in terms of the progression of irreversible disability in MS. Although MS is an autoimmune disease, focal inflammation may have only a limited effect on the course of diffuse neurodegeneration; once triggered by focal inflammation, but independent of it, subsequent progression of neurodegeneration seems to become a self-perpetuating process.

5. Conclusion

Does this mean that inflammation and relapses do not deserve consideration? Obviously not. Assuming that the disease were detected at the very beginning of the autoimmune process, immunoactive drugs might be administered immediately and could presumably show a dramatic efficacy. Unfortunately, when MS becomes clinically apparent, the disease, in most cases, is already well-established. Currently approved immunoactive drugs can help control inflammation and relapses, but even powerful agents, such as Campath-1H or mitoxantrone, do not prevent the subsequent accumulation of irreversible disability and neurodegeneration. Therefore, in the next few years, in addition to the commonly used anti-inflammatory treatments, major efforts should be expended on the development of powerful tools to protect the CNS from degeneration and enhance repair [66–68].

References

[1] Schumacher G, Beebe G, Kibler R, et al. Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS. Ann N Y Acad Sci 1965;122:552–68.

[2] Poser C, Paty D, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31.

[3] Confavreux C, Compston D, Hommes O, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671–6.

[4] Thompson A, Polman C, Miller D, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085–96.

[5] McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50: 121–7.

[6] Youl B, Turano G, Miller D, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991;114:2437–50.

[7] Fox N, Jenkins R, Lary S, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000;54:807–12.

[8] Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257–66.

[9] Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–8.

[10] Confavreux C. Relapses, progression, inflammation and neurodegeneration in multiple sclerosis: a changing view. ACNR 2002;2:7–9.

[11] Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–82.

[12] Lublin F, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–32.

[13] Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281–300.

[14] Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographical based study. II. Predictive value of the early clinical course. Brain 1989;112:1419–28.

[15] Weinshenker B, Rice GP, Noseworthy J, et al. The natural history of multiple sclerosis: a geographical based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045–56.

[16] Trapp B, Peterson J, Ransohoff R, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:27885.

[17] Evangelou N, Esiri M, Smith S, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391–5.

[18] Hohlfeld T, Kerschensteiner M, Stadelmann C, et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000;107:161–6.

[19] Lublin F. Reingold S for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course: results of an international survey. Neurology 1996;46:907–11.

[20] Cottrel D, Kremenchutzky M, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625–39.

[21] Kremenchutzky M, Cottrel D, Rice G, et al. The natural history of multiple sclerosis: a geographical based study. VII. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941–50.

[22] PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504.

[23] Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268–76.

[24] Liu C, Blumhardt L. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450–7.

[25] Phadke J. Clinical aspects of multiple sclerosis in northeast Scotland with particular reference to its course and prognosis. Brain 1990;113:1597–628.

[26] Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 1993;116:117–34.

[27] Runmarker B, Andersson C, Oden A, et al. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994;241:597–604.

[28] Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300–6.

[29] Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998;51:765–72.

[30] Eriksson M, Andersen O, Runmarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003;9:260–74.

[31] Pittock S, Mayr W, McClelland R, et al. Progression of disability in MS: a population-based study in Olmsted County, Minnesota. Neurology 2003;60(Suppl. 1):P01.114.

[32] Andersson P, Waubant E, Gee L, et al. Multiple sclerosis that is progressive from the time of onset. Clinical characteristics and progression of disability. Arch Neurol 1999;56:1138–42.

[33] Müller R. Studies on disseminated sclerosis. With special reference to symptomatology, course and prognosis. Acta Med Scand 1949;133(Suppl. 222):1–214.

[34] Thygesen P. Prognosis in initial stage of disseminated primary demyelinating disease of central nervous system. Arch Neurol Psychiatry 1949;61:339–51.

[35] Hyllested K. Lethality, duration and mortality of disseminated sclerosis in Denmark. Acta Psychiatr Neurol Scand 1961;36:553–64.

[36] McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961;84:186–203.

[37] Fog T, Linneman F. The course of multiple sclerosis in 73 cases with computer designed curves. Acta Neurol Scand 1970;46(Suppl. 47):1–175.

[38] Leibowitz U, Alter M. Multiple sclerosis: clues to its cause. Amsterdam/London: North-Holland Publishing Company; 1973, 373 pp.

[39] Poser S, Hauptvogel H. Clinical data from 418 MS patients in relation to the diagnosis. First experiences with an optical mark reader documentation system. Acta Neurol Scand 1973;49:473–9.

[40] Kurtzke J, Beebe G, Nagler B, et al. Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chronic Dis 1977;30:819–30.

[41] Clark VA, Detels R, Visscher B, et al. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982;248:856–60.

[42] Poser S, Poser W, Schlaf G, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986;74:387–92.

[43] Phadke J. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north-east Scotland. J Neurol Neurosurg Psychiatry 1987;50:523–31.

[44] Minderhoud J, Van der Hoeven J, Prange A. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 1988;78:10–5.

[45] Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographical based study. I. Clinical course and disability. Brain 1989;112:133–46.

[46] Riise T, Gronning M, Fernandez O, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992;85:212–8.

[47] Midgard R, Albrektsen G, Riise T, et al. Prognostic factors for survival in multiple sclerosis: a longitudinal, population-based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995;58:417–21.

[48] Ebers G. Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al., editors. McAlpine's Multiple Sclerosis. 3rd ed. London: Churchill Livingstone; 1998. p. 191–221.

[49] The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–61.

[50] Jacobs L, Cookfair D, Rudick R, et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94.

[51] European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491–7.

[52] Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496–504.

[53] Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298–301.

[54] Coles A, Wing M, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296–304.

[55] Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multi-center study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112–8.

[56] Patti F, Cataldi L, Nicoletti F, et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404–7.

[57] Rice G, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54:1145–55.

[58] Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55:1714–8.

[59] Filippi M, Rovaris M, Rice G, et al. The effect of cladribine on T1 "black hole" changes in progressive MS. J Neurol Sci 2000;176:42–4.

[60] Inglese M, Mancardi G, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004;75:643–4.

[61] Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996;35:1263–8.

[62] Lee D, Weinblatt M. Rheumatoid arthritis. Lancet 2001;358:903–11.

[63] Patzold U, Pocklington P. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from. Acta Neurol Scand 1982;65:248–66.

[64] Confavreux C, Hutchinson M, Hours M, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998;339:285–91.

[65] Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319–26.

[66] Compston A. Brain repair. J Intern Med 1995;237:127–34.

[67] Scolding N. New cells from old. Lancet 2001;357:329–30.

[68] Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003;422:688–94.